A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
← catalyst calendarNCT06512883 · readout in 549 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
14estimated
Sites
15
Countries
Brazil, Canada, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-17 | actual | When the study began enrolling |
| Primary completion | 2028-02-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-14 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Hypereosinophilia Syndrome (HES)
Intervention
- Drug: Benralizumab — also filed as FASENRA
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs)
measured From screening (Week -4 to -1) until Week 52
Serum Concentrations of Benralizumab
measured Weeks 0, 12, 24, 25, 36, and 52
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed